OmniAb to Hold Research & Technology Virtual Event on November 9

Webcast to include an update on latest technology offerings and third quarter 2023 financial results

OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time. The event is expected to last approximately two hours and will include a review of the company’s latest technology offerings and financial results for the three and nine months ended September 30, 2023, which will be announced earlier that morning.

Matt Foehr, Chief Executive Officer, will be joined by members of OmniAb’s senior management team, with a Q&A session to follow management’s presentations.

The webcast and replay, including audio, video and presentation slides, will be available on the Investors portion of OmniAb’s website. Additional information about speakers and their presentations, as well as instructions about how to participate will be announced at a later date.

About OmniAb^®

OmniAb’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence^™ (BI) of our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic^® (transgenic rat) and OmniClic^® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur^™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. These proprietary technologies are joined with and leverage OmniDeep^™, which is a suite of in silico tools for therapeutic discovery and optimization that are woven throughout OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others.

The OmniAb suite of technologies span from BI-powered repertoire generation to cutting-edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231012819254/en/